K145

K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity[1].

Product Specifications

CAS Number

[1309444-75-4]

UNSPSC

12352005

Target

Apoptosis; SphK

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/k145.html

Solubility

10 mM in DMSO

Smiles

O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2

Molecular Formula

C18H24N2O3S

Molecular Weight

348.46

References & Citations

[1]Liu K, et al. Biological characterization of 3- (2-amino-ethyl) -5-[3- (4-butoxyl-phenyl) -propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8 (2) :e56471.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

SphK2

Citation 01

Am J Cancer Res. 2019 Mar 1;9 (3) :546-561.|Biochem Biophys Res Commun. 2017 Nov 4;493 (1) :286-290. |Channels. 2020 Dec;14 (1) :216-230.|Exp Mol Pathol. 2016 Feb;100 (1) :51-8. |Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Biochem Biophys Res Commun. 2021 Sep 28;580:1-6.